Apaxen

Apaxen is a privately held biotechnology company with the mission to provide innovative treatments for various therapeutic indications associated with chronic inflammation, primarily focusing on pulmonary arterial hypertension (PAH) and other fatal lung diseases. The company specializes in developing first-class small molecule inhibitors targeting "macrophage migration inhibitory factor (MIF)," a key regulator of innate immune response. Apaxen's lead compound, MFC-1040, is a selective small molecule MIF inhibitor for treating pulmonary arterial hypertension (PAH), a rare and fatal disease with significant unmet medical needs due to the symptomatic nature and low median survival rates associated with approved therapies. MFC-1040 has a unique mechanism of action with the potential to revolutionize the standard of care for PAH and other diseases associated with chronic inflammation.